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Abstract
Background: CD133-positive cells in hepatocellular carcinoma (HCC) exhibit cancer stem cell (CSC)-like
properties as well as resistance to chemotherapeutic agents and ionizing radiation; however, their function
remains unknown. In this paper, we identified a hitherto unknown mechanism to overcome CD133-induced
resistance to anticancer therapy.
Methods: We applied an alternative approach to enrich the CD133-positive HCC population by manipulating
3D culture conditions. Defense mechanisms against reactive oxygen species (ROS) in CSC spheroids were
evaluated by fluorescence image-based phenotypic screening system. Further, we studied the effect of
sulfasalazine on ROS defense system and synergistic therapeutic efficacy of anticancer therapies both in culture
and in vivo HCC xenograft mouse model.
Results: Here, we found that oxidative stress increase CD133 expression in HCC and increased CD133
expression enhanced the capacity of the defense system against ROS, and thereby play a central role in
resistance to liver cancer therapy. Moreover, ablation of CD133 attenuated not only the capacity for defense
against ROS, but also chemoresistance, in HCC through decreasing glutathione (GSH) levels in vitro.
Sulfasalazine, a potent xCT inhibitor that plays an important role in maintaining GSH levels, impaired the ROS
defense system and increased the therapeutic efficacy of anticancer therapies in CD133-positive HCC but not
CD133-negative HCC in vivo and in vitro.
Conclusion: These results strongly indicate functional roles for CD133 in ROS defense and in evading anticancer
therapies in HCC, and suggest that sulfasalazine, administered in combination with conventional chemotherapy, might be
an effective strategy against CD133-positive HCC cells.
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Background
Hepatocellular carcinoma (HCC) is the sixth most com-
mon malignant tumor, and the second leading cause of
cancer-related deaths in the world [1]. Over the past
decade, advances in treatment, medical device develop-
ment, surgical techniques, radiology, and liver trans-
plantation have resulted in considerable improvements
in therapy for HCC [2, 3]. However, the prognosis for
this disease is still very poor, because most types of HCC
are resistant to conventional chemotherapeutic agents
and have high recurrence after resection with curative
aim. Currently, the only chemotherapeutic agent for
HCC is sorafenib, however, it just expands the survival
only 2.8 months [4]. Therefore, the novel target and
agents for HCC is unmet need.
Cancer stem cells (CSCs) are identified by experiments
in which tumor cells are fractionated, characterized by
cell surface markers, and injected at limiting dilutions
into mice. Those populations that lead to tumor growth
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in the animal, and that lead to tumor growth when that
tumor is subsequently transplanted into a second ani-
mal, are considered as CSCs [5]. Studies have shown
that CSCs can be resistant to common forms of cancer
treatment such as chemo- and radiation therapy, result-
ing in tumor recurrence, metastasis, and treatment fail-
ure [6–8]. Therefore, deeper knowledge of the
interactions between cancer cells and CSCs are needed
to fully understand tumor development, progression,
and chemo-resistance in HCC. Recently, compelling evi-
dence has reported that HCC is hierarchically organized
and originates from a primitive stem/progenitor [9].
In particular, CD133 has drawn significant attention as
an important liver CSC marker. CD133 was the first
identified member of the prominin family of pentaspan
transmembrane (5-transmembrane) glycoproteins. It is
also commonly known in humans and rodents as Promi-
nin 1 (PROM1) [10]. In HCC, CD133-positive cells
exhibit liver CSC-like properties, such as high clonogeni-
city, tumorigenicity, and resistance to radiation [11, 12].
Other studies have shown that the presence of CD133-
positive cells in HCC patients after surgery is correlated
with early recurrence and poor prognosis [13, 14].
However, despite of extensive research efforts, the spe-
cific signaling pathway and mechanism of action by
which CD133-positive cells are able to evade conven-
tional therapies in HCC or other cancer types remain
largely unknown.
Reactive oxygen species (ROS), which are formed by
the capture of electrons by an oxygen atom, are chem-
ically reactive molecules that have essential functions in
living organisms [15]. In normal cells, moderate levels of
ROS are essential for cellular proliferation, differenti-
ation, and survival [16, 17]. On the other hand, chronic-
ally increased endogenous ROS levels lead to adaptive
changes that play pivotal roles in tumorigenesis, metas-
tasis, and drug resistance in diverse types of cancer cells.
Some anti-cancer drugs that increase ROS generation
or inhibit ROS elimination can induce a significant ac-
cumulation of ROS in cancer cells, leading to oxidative
damage and cell death [18]. In recent times, the regula-
tion of ROS levels in CSCs has emerged as an active
field of research. CSCs have lower levels of intracellular
ROS than do non-CSCs, possibly due to the increased
expression of free radical scavenging systems [19–21].
Studies have showed that specific molecules associated
with CSCs negatively regulate ROS levels, with a result-
ant increase in stemness. CD44 is one such molecule
that has been associated with CSCs in several types of
tumors, promotes ROS resistance by interacting with
and stabilizing the cystine/glutamate transporter xCT
in human gastrointestinal cancer, and increased CD13
expression reduces ROS levels, promoting the survival
of liver cancer stem cells via an epithelial-mesenchymal
transition-like phenomenon [22, 23]. However, the roles
of CD133 in ROS regulation have not been reported.
In this paper, we show that CD133-positive HCC cells
exhibit strong resistance to reactive oxygen species
(ROS) via upregulation of glutathione (GSH) levels, and
thereby play a central role in resistance to liver cancer
therapy. Based on this functional roles of CD133, we
also found that sulfasalazine specially modulates the
redox status in CD133-positive HCC, and could thereby
sensitize CD133-positive HCC to chemotherapeutic
treatment. Our results suggest that the combination of
sulfasalazine and conventional chemotherapy could po-




Huh7, Hep3B, PLC/PRF/5 and HepG2 cells (human
HCC lines) were obtained from the Korean Cell Line
Bank. Human HCC cell line Huh6 was kindly provided
by Dr. Ralf Bartenschlager (University of Heidelberg,
Germany) and Fa2N-4 cells (human immortalized
hepatocyte cell line) were purchased from Xenotech
(Lenexa, KS, USA). HCC cell lines were cultured in
Dulbecco’s minimal essential medium (DMEM;
Welgene, Korea, LM001-05) supplemented with heat-
inactivated 10% fetal bovine serum (FBS; Gibco,
Gaitherburg, MD, USA) and 100U/ml Penicillin and
100 μg/ml Streptomycin (Gibco) at humidified 37 °C
incubator under 5% CO2. Fa2N-4 cells were plated in
collagen-coated plates. After cell attachment (approxi-
mately 3 ~ 6 h), serum-containing plating medium
(XenoTech, K4000) was replaced with supporting cul-
ture medium (XenoTech, K4100.X).
Primary cell culture
HCC tissue was cut into 3-mm3 pieces and washed with
4 °C Hank’s balanced salt solution (Lonza, Basel,
Switzerland) supplemented with 1× antibiotic-antimycotic
(A/A) solution (Sigma-Aldrich, St Louis, MO, USA) and
1× penicillin-streptomycin (P/S) (Lonza) in 100-mm Petri
dishes. After three washes with DMEM/nutrient mixture
F-12 (DMEM/F12; Gibco) supplemented with 10% FBS,
1× A/A solution, and 1× P/S, the cells were resuspended
in 10 ml of the same solution and incubated at 4 °C for
16 h. Next, tissue was washed with fresh DMEM/F12 and
incubated with 2 ml of 2× collagenase II (BD Biosciences,
Franklin Lakes, NJ, USA) at 37 °C in a shaking chamber
for 90 min. After incubation, the tissues were washed with
DMEM/F12 several times until the supernatant was clear.
The pellet was resuspended in hepatocyte basal medium
(Lonza, CC3199) containing 1× A/A solution, 10% FBS,
and 5 μg/ml hepatocyte growth factor (R&D systems,
Song et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:38 Page 2 of 15
Minneapolis, MN, USA) and plated on collagen type I-
coated T-25 flasks (BD Biosciences) with 5×105cells.
Formation of liver cancer stem cell (LCSC) spheroids
Huh7 were seeded in a very low density on 100-mm dish
(5x105cells/10 cm2). After attachment of cells, complete
medium were changed to DMEM/F12 (Gibco, 10565–
018) supplemented with 1 × B27 (Invitrogen, Eugene, OR,
USA), 20 ng/ml basic fibroblast growth factor (Invitrogen),
20 ng/ml epidermal growth factor (EGF, Invitrogen),
25 μg/ml insulin (Sigma) (LCSC media). After cultivation
for 7 ~ 10 days without changing the medium, floating
spheroids were collected and moved to low-attach 6-well
plate (Corning, NY, USA) for subculture or 384-well cul-
ture plate (Greiner Bio-one, Monroe, NC, USA) for
immunostaining.
Formation of HCC spheroids
For the HCC spheroids culture, slowly pipette the 8 μl
of Matrigel (BD bioscience) directly on surface, carefully
spread to avoid bubbles, in 384-well culture plates and
incubated at 37 °C until Matrigel was solidified. Trypsi-
nized cells were centrifuged at 1200 rpm and resus-
pended in culture medium and plated onto the Matrigel
coated plates at a density of 2 × 103cells/well. Cells were
incubated for 30 min at 37 °C to settle to the Matrigel
and slowly added 10% Matrigel-medium to the each
wells. After maintaining for 5 days, Matrigel-medium
was replaced every 2 days. For immunostaining, they
were washed with 1 mM Glycine (Sigma) carefully, and
then spheroid were moved to 384-well culture plate.
Detection of drug sensitivity in spheroids
For the drug sensitivity with or without pretreating of
sulfasalazine in spheroids, LCSC spheroids and HCC
spheroids were transferred to 96-well plate. Spheroid
were treated with anti-cancer drug for 6 ~ 8 days, and
spheroids were examined their size using Operetta® High
Content Screening (HCS) System using × 10 objective in
bright field. For SASP pretreating study, spheroid was
treated with 200 μM sulfasalazine for 24 h before anti-
cancer drug treatment.
Reagent and antibodies
Hoechst 33342 (H3570, 1:500), 2′,7′-dichlorodihydro-
fluorescein diacetate, acetyl ester (CM-H2DCFDA. C6827,
1:1000), ThiolTracker™ violet (T10095, 1:500), Alexa
Fluor® 633 Phalloidin (A22284, 1:100), Goat anti-mouse
Alexa Fluor® 488 (A11001, 1:500), Goat anti-rabbit Alexa
Fluor® 633 (A21070, 1:500), Goat anti-mouse Alexa Fluor®
633 (A21050, 1:500) and Goat anti-rabbit Alexa Fluor®
488 (A11008, 1:500) were purchased from Molecular
Probes (Invitrogen). Rabbit monoclonal anti-CD44
(EPR10133Y clone, ab51037, 1:1000) rabbit polyclonal
anti-EpCAM (ab71916, 1:1000) and mouse monoclonal
anti-CD90 (ab133350, 1:1000) were purchased from
Abcam (CSP, Cambridge, England). Methotrexate,
Doxorubicin, Cisplatin, Sorafenib, Sulfasalazine (SASP),
Buthionine sulphoximine (BSO), Arsenic trioxide, Eto-
poside and Hydrogen peroxide (H2O2) were purchased
from Sigma Chemicals. Mouse monoclonal anti-
CD133/1 (AC133, 130-090-422, 1:100) was purchased
from Miltenyi biotec (Bergisch Gladbach, Germany).
Rabbit polyclonal anti-AFP (Dako, Denmark A/S,
Denmark, A000829. 1:500) and mouse monoclonal
anti-β-actin (Sigma, A5441, 1:10,000) antibodies were
purchased from each of the indicated companies.
HCS imaging assay technology
Cells were seeded at a 2,500 cells/well density for 72 h
incubation and 1,500cells/well density for 96 h incuba-
tion in 384-well plate (90% of confluence in analyzing
day). After being treated with the indicated concentra-
tions of various drugs for proper time, cells were washed
with Dulbecco’s phosphate buffered saline (DPBS; Wel-
gene) and stained with fluorescent probes or antibody.
Automated live-cell multispectral image acquisition was
performed on the Operetta® HCS System using × 20 ob-
jective (Perkin Elmer, Waltham, MA, USA). The fluores-
cence images were captured according to the optimal
excitation and emission wavelengths of each probe. To
capture enough cells (>100) for analysis, five image fields
starting at the center of well were collected from each
well. Image analysis was performed using the Image
Mining software. A series of measurements from the nu-
clei, ROS, and ThiolTracker™ channel images were ob-
tained for each drugs.
siRNA transfection
siRNA probes were designed by and purchased from Dhar-
macon (Lafayette, CO, USA). Huh7 cells were seeded with
1x106cells/10 cm2 and the medium was replaced with
Opti-MEM (Gibco) when the cell density reached 40–50%.
The sequences of siCD133 was as follows: CD133 #1, 5′-
GCUAAGUACUAUCGUCGAA-3′; CD133 #2, 5′-GAAC
AAGUUUACAGUGACU-3′; CD133 #3, 5′-GAAGUAU
GGGAGAACAAUA-3′; CD133 #4, 5′-UCACAAUCCU-
GUUAUGACA-3′; Cells were co-transfected with the four
siRNAs targeting CD133 (siCD133) scramble (siCont) for
24 h using Lipofectamine® 2000 (Invitrogen).
Cell sorting
Huh7 cells were analyzed by fluorescence-activating cell
sorting (FACS; BD bioscience). The cells were harvested
using 0.05% trypsin (Gibco), washed twice with DPBS
supplemented with 5% FBS and resuspended in DPBS
supplemented with 10% FBS with mouse anti-human
CD133/1 antibody (Miltenyi Biotec) for 30 min at 4 °C.
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The cells were washed twice with pre-cooled DPBS and
centrifuged at 1200 rpm at 4 °C and incubated in DPBS
supplemented with 10% FBS with goat anti-mouse Alexa
Fluor® 488 for 30 min at 4 °C in dark. After washing with
DPBS twice, cells were sorted by FACS. CD133−nega-
tive and CD133-positive HCC were collected for fur-
ther experiments, and they were cultured in DMEM
supplemented with 10% FBS with 1% of penicillin/
streptomycin.
Flow cytometry analysis
For investigating the CD133 population after CD133
positive cell sorting or transfected with siCD133, cells
were trypsinized and washed twice with DPBS supple-
mented with 5% FBS and resuspended in DPBS supple-
mented with 10% FBS with mouse anti-human CD133/1
antibody for 30 min at 4 °C. The cells were washed with
DPBS and centrifuged at 1200 rpm a 4 °C and incubated
n DPBS supplemented with 10% FBS with goat anti-
mouse Alexa Fluor® 488 for 30 min at 4 °C in dark. After
washing with DPBS twice, cells were analyzed by flow
cytometry.
For analyzing of cellular ROS levels, the cells were in-
cubated with 10 mM of CM-H2DCFDA at 37 °C for
10 min in the dark, and washed with DPBS. For detect-
ing the GSH levels, the cells were washed with DPBS
containing the Ca2+ and Mg2+ and then cells were
treated with 20 mM ThiolTracker™ in DBPS containing
the Ca2+ and Mg2+ at 37 °C incubator for 30 min in the
dark. Washed cells were then trypsinized and suspended
for flow cytometry, intensity of 405 nm were measured
for detecting GSH level.
Analysis of total glutathione (GSH) activity
Assay for total GSH activity was performed using assay
kit (Sigma) according to the manufacturer’s protocol.
The method is based on the 5,5′-dithiobis-(2-nitroben-
zoic acid) (DTNB) reaction and the products were read
at 412 nm.
Polyacrylamide gel electrophoresis (PAGE) and western
blot analysis
Cells were solubilized in lysis buffer (3 M, Maplewood,
MN, USA), the samples were boiled for 5 min, and equal
amounts of protein (10–30 μg/well) were separated on 8
or 10% SDS-PAGE gels. After electrophoresis, the pro-
teins were transferred onto a polyvinylidene difluoride
(PVDF) membrane (Millipore, Billerica, MA, USA) and
blocked with 5% skim milk for 30 min at R.T. After
blocking, the PVDF membranes were incubated with
anti-CD133, xCT and β-actin for 16 h at 4 °C. After
washing, the blots were incubated with horseradish
peroxidase-conjugated secondary antibody (Cell Signaling
Technology, Danvers, MA, USA) at a 1:10000 dilution,
and specific bands were visualized by enhanced chemi-
luminescence (ECL; Thermo Scientific) and recorded
on X-Omat AR films (Eastman Kodak Co., Rochester,
NY, USA).
Irradiation
Cells were plated in 100-mm dish and 6-well plate for
each experiment, and tumor-bared mice were treated
with 1Gy, 2Gy, 4Gy (for colony forming assay), 5Gy
(xenografted mice), 10 Gy (cell survival, ROS accumula-
tion) of ioning radiation (IR) using a 6 MV photon beam
linear accelerator (CL/1800, Varian Medical System Inc.,
Palo Alto, CA, USA) [24, 25].
Clonogenic survival assays
Briefly, Huh7-siCont and Huh7-siCD133 cells were
seeded into 6-well plates (Nunc, Roskilde, Denmark) at a
density of 500 cells/well and allowed to grow for 24 h.
The cells were then treated with SASP (100 μM or
200 μM) for further 24 h [26]. The SASP-containing
media were then discarded, and the cells were washed
with DPBS and culture to form colonies in complete
medium after irradiation (1, 2, 4Gy).
Tumor xenografts in nude mice
Huh7 (5x106cells) with 95% viability were injected
subcutaneously into the hind legs of 6-week-old
BALB/c athymic nude mice (SLC Inc., Hamamatsu,
Japan) [27, 28]. When tumors reached a volume of
200–250 mm3, mice were randomly allocated to four
groups as follows: (1) the tumor control group, (2) the
SASP group (5 mg/20 g, 9 days) [22], (3) the IR group
(5Gy), and (4) the SASP plus IR group. Each group
contained three mice. Tumor volumes were deter-
mined using the following formula: (L × I2)/2, where
L = tumor length and I = tumor width. Dimensions
were determined using calipers. Local tumor irradi-
ation was performed under anesthesia using a 6 MV
photon beam linear accelerator (CL/1800). SASP was
dissolved in saline (0.9% NaCl) and injected for intra-
peritoneal for 9 days. The mice were sacrificed for im-
munohistochemistry, RT-PCR and western blot after
15 days from SASP injection.
Statistical analysis
All experiments were performed at least three times.
The results are expressed as the mean ± SD. Statistical
analysis was performed using the Student’s t-test.
Results
CD133-positive cells have cancer stem cell-like properties
in liver cancer
In order to overcome resistance to chemotherapy in
cancer stem cells (CSCs), these CSCs should be
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characterized in particular cancer types. To identify CSC
markers specific to HCC, we generated HCC spheroid
and liver cancer stem cell (LCSC) spheroid from the
Huh7 cell line in different culture conditions to overcome
the shortcomings of the monolayer culture system in vitro.
Additionally, Huh7 is the best proper human HCC cell
lines for high content screening, cell sorting with CD133
antibody, and xenograft mouse model, therefore, we used
Huh7 cell lines as representative human HCC cells. LCSC
spheroids were grown in serum-free medium supple-
mented with growth factors. Only floating spheroids were
collected as the LCSC population (Fig. 1a, upper). On the
other hand, HCC spheroids were generated on the
Matrigel-coated plates in DMEM with 10% fetal bovine
serum (FBS) (Fig. 1a, lower). In order to analyze the differ-
ences between spheroids grown in different environments,
we compared various characteristics, such as functional
structure, drug sensitivity, and composition, between the
LCSC and HCC spheroids.
Since bile canaliculi, which play an important role in
maintaining liver function, contain many F-actin micro-
filaments, we compared the F-actin pattern to fine dif-
ferent morphological signatures between LCSC and
HCC spheroids. F-actin staining was concentrated into
bile canaliculi-like structures (indicated by white arrows
in Fig. 1a) in HCC spheroids, while F-actin merely local-
ized to cell membranes in LCSC spheroids (Fig. 1a).
Moreover, LCSC spheroids express a lower level of
hepatocyte-related mRNA (albumin, HNF1a) and higher
level of stem cell-related mRNA (OCT4 and TERT)
compared to HCC spheroids (Additional file 1: Figure S1).
Thus, we speculated that LCSC spheroids could not per-
form the main functions of liver cells, since they did not
exhibit similar architecture to spheroids derived from neo-
plastic liver tissue, compared to HCC spheroids.
Next, we investigated cell viability in both types of
spheroids following exposure to common anti-cancer
drugs against HCC (Fig. 1b). Following treatment with
sorafenib and doxorubicin, we observed a significant de-
crease in the size of HCC spheroids (sorafenib: 421 μm
to 312 μm, doxorubicin: 471 μm to 342 μm) whereas the
average size of the LCSC spheroids remained the same
or continuously increased (sorafenib: 332 μm to 487 μm,
doxorubicin: 418 μm to 672 μm). We obtained similar
results with other anticancer drugs such as taxol and
etoposide (Additional file 1: Figure S2). These results
demonstrate that LCSC spheroids have strong resist-
ance to chemotherapy compared to HCC spheroids.
Moreover, these results suggest that the tumor micro-
environment plays a critical role in modulating drug
sensitivity, because differences in tumor growth envi-
ronments resulted in different sensitivities to chemo-
therapy, even though these spheroids were formed
from same HCC cell line.
To determine the underlying cause of the increased
drug resistance in LCSC spheroids, we investigated the
expression of CSC-associated cell surface markers
(CD133, EpCAM, CD90, CD44) in LCSC spheroids. To
present the spheroid staining image, we set the Z’ stack
on spheroid using the high content screening system. It
means that every 10 μm images on spheroid were taken
and merged together. CD133 staining in HCC spheroid
is uneven, on the other hand, expression of CD133 in
LCSC spheroid was much even compared to HCC
spheroid. LCSC spheroids contained a large population
of CD133-positive cells, whereas HCC spheroids in-
cluded only a small population of CD133-positive cells,
as these HCC spheroids exhibit relatively higher hetero-
geneity (Fig. 1c). Two kinds of spheroids were derived
from the Huh7 cells, however, they showed different F-
actin pattern and CD133 expression.
Based on earlier observations that CD133-positive cells
exhibit resistance to chemotherapy, we investigated sen-
sitivities to various anticancer drugs in monolayer cul-
tured HCC using the high content screening (HCS)
system. In Fig. 1d, we tested the chemoresistance in
HCC cell line using cisplatin, doxorubicin, etoposide,
methotrexate, As2O3 and sorafenib. Except sorafenib
and cisplatin, other drugs are not commonly used in
HCC patients, however, we would like to examine the
ROS inducing drugs in cancer stem cells. Indeed, the
CD133-positive cell population exhibited strong viability
in the presence of anti-cancer drugs in contrast to a de-
crease in total cell number in HCC (Fig. 1d). These re-
sults indicated that LCSC spheroids and HCC spheroids
have different composition and drug sensitivities, al-
though both spheroids originated from the same HCC
cell line. Collectively, these results suggest that CD133-
positive cells possess cancer stem cell-like characters in
liver cancer.
Oxidative stress-induced CD133 overexpression facilitates
an efficient ROS defense system
In order to overcome CD133-induced chemoresistance,
we focused on elucidating the functional roles of CD133
in chemoresistance. To define detailed mechanisms of
drug resistance in the CD133-positive cell population,
we investigated differences between CD133-positive and
CD133-negative HCC populations by utilizing LCSC
spheroids. Following the generation of LCSC spheroids,
we modified their environment from the stem cell-
permissive medium (DMEM/F12 supplemented 1× B27,
20 ng/ml bFGF, 20 ng/ml EGF, 25ug/ml insulin) to a
general HCC culture medium (DMEM-high glucose
supplemented with 10% FBS) to make CD133-negative
HCC populations, which were differentiated from LCSC
spheroids. After 2 days, we observed that LCSC spher-
oids were tightly attached on the bottom of the culture
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dish. Under these conditions, we investigated the pattern
of reactive oxygen species (ROS) accumulation in live
conditions by fluorescence microscopy after staining
with CM-H2DCFDA, since ROS are generally known as
mediators of apoptosis induced by various anti-cancer
drugs. ROS were noticeably detected in the outer surface
cells of the LCSC spheroids, whereas relatively small
amounts of ROS were seen in the center of the LCSC
spheroids (Fig. 2a, upper panel).
Next, we investigated the distribution of CD133 ex-
pression at the same positions. The center of the LCSC
spheroid maintained high CD133 expression, whereas
Fig. 1 The CD133-positive HCC population has cancer stem cell-like properties in liver cancer. a Schematic of the experimental procedure for
the generation of LCSC and HCC spheroids (left panel). Spheroids were stained with phalloidin-633, which is staining the F-actin for structure
morphology, and Hoechst 33342 for nucleus staining in order to compare the different morphological signatures between the two spheroids.
b The drug sensitivities of LCSC and HCC spheroids were examined after treatment with 10 μM sorafenib and doxorubicin for 8 days. The size of
the spheroid was measured each day using the Operetta® High Content Screening System using a × 10 objective (scale bar: 200 μm). c LCSC and
HCC spheroids were stained with CD133 and phalloidin-633, which identified CSCs in both spheroids. d Chemoresistance of the CD133-positive
HCC population to anti-cancer drugs was detected using the HCS system. CD133 staining was carried out following drug treatment for 48 h
(upper panel); mean values ± SD from two independent experiments for cell survival ratio relative to the value for control are shown in the
lower panel
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the outer surface cells of the LCSC spheroid quickly lost
CD133 expression (Fig. 2a, lower panel). In terms of the
macroscopic trends in ROS accumulation and CD133
expression, ROS content tended to be inversely propor-
tional to CD133 expression. We also detected that cells
with high CD133 expression could inhibit ROS produc-
tion, relative to cells with low CD133 expression, follow-
ing exposure to oxidative stress (200 mM, H2O2) in
conventional 2D culture conditions (Fig. 2b).
To ascertain the effect of CD133 on ROS regulation,
we selected four human HCC lines that exhibit different
expression levels of CD133. FACS and immunostaining
analysis revealed that different HCC cell lines have dif-
ferent proportions of CD133-positive cells, in the follow-
ing order: Huh7 (98.2%), Hep3B (97.7%) > PLC/PRF/5
(77.1%) > Huh7.5 (39.0%) (Fig. 2c). When these HCC
lines were exposed to H2O2, remarkably, ROS accumula-
tion was inversely proportional to CD133 expression in
the order Huh7.5 > PLC/PRF/5 > Huh7, Hep3B (Fig. 2d).
We next studied whether the expression of CD133
could be modulated by oxidative stress. For this, HCC






Fig. 2 Overexpression of CD133 inhibits ROS accumulation. a LCSC spheroids were reattached in a 384-well culture plate and stained with
CM-H2DCFDA and CD133 to investigate the relationship between CD133 expression and intracellular ROS levels. b Expression of CD133 and
ROS accumulation were detected after treatment with 200 μM H2O2 for 20 min in 2D culture condition. c Expression of CD133 in HCC cell
lines was measured using flow cytometry and immunostaining analysis. d HCC cell lines were treated with 200 μM H2O2 for 20 min. ROS accumulation
was analyzed by flow cytometry. e-f Huh7 cells were treated with the indicated concentrations of H2O2 and time. Whole cell lysates were then prepared
and assessed by western blotting. Expression of CD133 was examined depend on the concentration (e) and treatment time (f) of H2O2. ß-actin
was used as control
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expression analysis. Treatment with H2O2 significantly in-
creased CD133 expression in a dose-dependent manner
until 200 μM (Fig. 2e) and time-dependent manner until
60 min (Fig. 2f) in HCC. These results suggest that the oxi-
dative stress increase CD133 expression and overexpres-
sion of CD133 may play a role in ROS defense in HCC.
Increased CD133 expression reduces intracellular ROS via
upregulation of GSH levels and thereby promotes
resistance to anti-cancer therapies
To elucidate the functional relevance of CD133 expres-
sion to intracellular ROS levels, we sorted CD133-
positive and CD133-negative HCC cells from Huh7 cells
and then we confirmed sorting efficiency by western
blotting against CD133 (Fig. 3a). Western blotting
showed that CD133-positive and CD133-negative HCC
cells did not exhibit differences in the expression of
other CSC-associated cell surface markers, such as
EpCAM, CD90, CD44, and AFP and expression of CD44
was hardly detected in huh7 cells (Fig. 3b). These results
represented that difference of CD133 expression could
not alter the expression of other CSC-associated cell sur-
face markers.
Next, we treated H2O2 in CD133-positive and
CD133-negative HCC cells. ROS production was obvi-
ously increased in CD133-negative HCC cells, whereas
significant ROS accumulation was not observed in
CD133-positive HCC cells following oxidative stress
(Fig. 3c). To assess the effects of CD133 on the regula-
tion of ROS accumulation by chemotherapeutic agents
and ionizing radiation (IR), we exposed both popula-
tions to various ROS inducers such as As2O3, cisplatin,
methotreaxate and IR. CD133-negative HCC cells dis-
played significant increase in ROS accumulation by
ROS inducers, however, CD133-positive HCC cells did
not exhibit enhanced ROS accumulation under the
same conditions (Fig. 3d).
For a more accurate analysis, we also investigated the
effects of CD133 ablation on the ROS defense system.
SiRNA of CD133 (siCD133) efficiently depleted CD133
protein levels, whereas control siRNA (siCont) treatment
did not (Fig. 4a). CD133-deficient cells manifested a
greater increase in ROS than did siCont-transfected
cells following exposure to ROS inducers (MTX, cis-
platin, and IR) (Fig. 4b). Because depletion of CD133 in-
creased ROS accumulation, we next examined whether
depletion of CD133 could modulate cell fate. CD133 de-
pletion facilitated chemotherapy or radiation-induced
cell death (Fig. 4c). Taken together, these results suggest
that CD133 might promote the ROS defense system and
thus enhance resistance to chemotherapy and IR treat-
ment in HCC.
Because cancer cells are protected against oxidative
stress by an interacting network of antioxidant enzymes,
we investigated the expression of antioxidant genes in
CD133-depleted Huh7 cells by reverse transcription
polymerase chain reaction (RT-PCR) (Additional file 1:
Figure S3). However, CD133 depletion did not affect the
expression of antioxidant genes. This suggests that
CD133-mediated ROS resistance is independent of the
regulation of antioxidant gene expression. Among antioxi-
dant molecules, glutathione (GSH) is found in particularly
high levels in the liver tissues and serves in detoxification
metabolism. Thus, we compared GSH levels between the
central cells and outer surface cells of LCSC spheroids like
as Fig. 2a. The cellular level of GSH was estimated by
staining of ThiolTracker™ Violet, as GSH represents the
majority of intracellular free thiols in the cell. As expected,
large amounts of GSH presented in the cells inside the
LCSC spheroid, relative to the outer surface cells of the
LCSC spheroid (Fig. 4d). FACS analysis also clearly re-
vealed that CD133 depletion significantly increased ROS
accumulation via inhibition of GSH levels (Fig. 4e). Taken
together, these results suggest that CD133 attenuates
intracellular ROS accumulation through the enhancement
of GSH levels and thereby promotes resistance to anti-
cancer therapy in HCC.
Sulfasalazine enhances the efficiency of anticancer
therapies in CD133-positive HCC but not CD133-negative
HCC
To explore the underlying mechanism by which CD133
contributes to GSH synthesis, we investigated the effects
of GSH inhibitors, which deplete GSH by inhibiting its
synthesis, in CD133-positive and CD133-negative HCC.
Buthionine sulphoximine (BSO) is an inhibitor of
gamma-glutamylcysteine synthetase (gamma-GCS), and
sulfasalazine (SASP) is a specific inhibitor of xCT-
mediated cystine transport. BSO inhibited GSH levels
and increased endogenous ROS to a similar extent in
both populations (Fig. 5a), whereas SASP treatment re-
sulted in higher GSH inhibition and ROS production in
CD133-positive HCC cells than in CD133-negative HCC
cells (Fig. 5b). We also examined total GSH activity
using assay kit, and they exhibited similar effect as
shown in Fig. 5a, b (Additional file 1: Figure S4-A, B).
Moreover, the strong ROS defense capacity of CD133
positive cells following H2O2 exposure was attenuated
by pretreatment with SASP but not by pretreatment
with BSO (Fig. 5c).
Next, we investigated whether pretreatment with SASP
can overcome resistance to anticancer therapy in
CD133-positive HCC cells. Here, we pre-treated sulfa-
salazine 24 h before the anti-cancer treatment, because
we investigated the changing levels of reduced GSH and
ROS after treatment with sulfasalazine for 24 h with
lower concentration than 200 μM in Fig. 5b.
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Cell number was measured following treatment with
cisplatin, doxorubicin, which can induce ROS accumula-
tion, with or without pretreatment with sulfasalazine in
CD133-positive HCC and CD133-negative HCC cells:
pretreatment with sulfasalazine dramatically enhanced
sensitivity to anticancer drugs in CD133-positive HCC
but not CD133-negative HCC (Fig. 5d).
To confirm our results, we further investigated
whether pretreatment with sulfasalazine affected drug
resistance on LCSCs spheroids. Combination treatment
with SASP and existing anticancer therapies such as cis-
platin, doxorubicin significantly attenuated the strong
drug resistance of LCSCs spheroids (Fig. 5e). We also in-




Fig. 3 CD133-positive HCC cells have an efficient ROS defense system. a Western blot analysis of CD133 after sorting of CD133-negative and
CD133-positive HCC from Huh7 cells. b Expression of CSC-related cell surface markers (EpCAM, CD90, CD44, CD24, AFP) were examined in
CD133-negative HCC and CD133-positive HCC by western blotting. c ROS accumulation in CD133-negative and CD133-positive HCC was
measured after treatment with 200 μM H2O2 for 20 min. The data shown were from three independent experiments relative to the value for
control. d CD133-negative and CD133-positive HCC were treated with the indicated concentrations of MTX, cisplatin, and As2O3. To examine
the effect of radiation, cells were treated with 10 Gy radiation. For ROS level measurement, cells were stained with CM-H2DCFDA and analyzed
by the HCS system after 12 h treatment with anti-cancer drugs and radiation treatment
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SASP and anticancer therapies in primary HCC tumors
to provide better physiological relevance and applicabil-
ity, and found pronounced therapeutic efficacy when
SASP was combined with cisplatin and doxorubicin to
treat 4 kinds of human primary HCC cell types (Fig. 5f ).
Ionizing radiation (IR) instantaneously causes the for-
mation of water radiolysis products that contain some
ROS. We also investigated whether pretreatment with
sulfasalazine induced synergistic effect with IR treatment
in HCC. A colony-forming assay revealed that pretreat-
ment with SASP could enhance the efficiency of IR ther-
apy in HCC with high levels of CD133 (Fig. 6a).
To determine whether SASP could sensitize an in vivo
system to IR, we examined the growth of implanted
Huh7 xenograft tumors. Administration of SASP alone
showed just a subtle reduction of tumor growth and IR
alone did not induced significant tumor regression.





Fig. 4 CD133 regulates intercellular ROS via upregulation of GSH levels and leads to resistance to anti-cancer therapies. a Huh7 was transfected
with siCont and siCD133, and their efficiency was examined by western blot analysis. b For the measurement of ROS levels, Huh7-siCont and
Huh7-siCD133 cells were treated with the indicated concentrations of MTX and cisplatin for 12 h and 5 Gy of radiation. c Huh7-siCont and
Huh7-siCD133 cells were treated with the indicated concentrations of MTX and cisplatin for cell survival analysis. After treatment for 48 h,
nuclei were stained with Hoechst33342 and counted. For the colony-forming assay, Huh7-siCont and Huh7-siCD133 cells were treated with 1,
2, or 4 Gy of radiation. Cells were allowed to grow for 14 days, stained with trypan blue, and scored. Data represent values ± SD from three
independent experiments relative to the value for control. d LCSC spheroids were reattached on a 384-well culture plate and GSH levels were
determined by ThiolTracker™ Violet staining using the HCS System. e CD133 levels, ROS accumulation, and GSH were investigated by flow
cytometry in Huh7-siCont and Huh7-siCD133. Each value of Huh7-siCD133 was normalized to Huh7-siCont. *p < 0.05. **p < 0.005
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inhibited tumor volume, versus mice treated with IR
alone (Fig. 6b). These data suggested that SASP could be
sensitizer for highly efficient treatment of IR.
Next, we examined whether SASP has a sensitizing effect
on CD133-positive cells, specifically in HCC. Immunohisto-
chemical analysis revealed that IR plus pretreatment with
Fig. 5 Sulfasalazine (SASP), an inhibitor of xCT, overcomes chemoresistance to anti-cancer therapies in CD133-positive HCC but not in CD133-
negative HCC. a, b ROS accumulation and reduced glutathione were measured by treating with the indicated concentrations of (a) buthionine
sulphoximine (BSO), and (b) sulfasalazine (SASP) for 24 h in CD133-negative and CD133-positive HCC. After treatment, levels of ROS and GSH were
examined using the HCS System via staining with CM-H2DCFDA and ThiolTracker™ Violet. c CD133-negative and CD133-positive HCC were
pretreated with SASP or BSO before being treated with 200 μM H2O2 for 24 h. After treatment, levels of ROS was examined using the HCS System.
d Dose response curve of CD133-negative and CD133-positive HCC cells, constructed from the results of pretreatment with 200 μM SASP for 24 h
before cisplatin, MTX, and sorafenib treatment with indicated concentration for further 48 h. After 48 h of drug treatment, the nucleus was stained
with Hoechst33342 and counted (upper panel). e LCSC spheroids were formed and treated with doxorubicin, cisplatin for 6 days with or without
pretreatment with 200 μM SASP. The size of LCSCs was detected with bright field microscopy with a 10 × objective (scale bar: 100 μm). f Human
primary HCC cells were treated with anti-cancer drugs (cisplatin, doxorubicin) for 48 h, with or without pretreatment with 200 μM SASP for 24 h.
Nuclei were stained with Hoechst33342 and examined using the HCS System. All data are mean values ± SD from two independent experiments.
*p < 0.05, **p < 0.005
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SASP significantly reduced the CD133-positive cell
population in Huh7 tumor cells in vivo compared with
treatment with IR alone (Fig. 6c). These results indicate
that SASP can sensitize CD133-positive HCC cells to
available anti-cancer therapies by reducing their ROS
defense capacity. Taken together, our data suggest that
treatment with SASP suppresses GSH synthesis and in-
creases ROS levels in CD133-positive HCC cells,
thereby facilitating the robust therapeutic activity of
combined SASP and anticancer therapies in human
liver carcinomas.
Discussion
HCC is one of the most malignant human cancers, with
high mortality rates worldwide in spite of early detection
and improvements in therapeutic technology. Nowadays,
surgical resection is considered as a first-line therapy for
HCC, whereas systemic chemotherapy plays an integral
role for patients with advanced HCC for whom surgery
is not a feasible option [29]. However, the effects of che-
motherapeutics such as sorafenib [30] and cisplatin [31]
on advanced HCC are extremely limited, because most




Fig. 6 Pretreatment with SASP eliminates the CD133-positive HCC population combined with anticancer therapies in vivo and in vitro. a The
colony-forming assay was performed in Huh7-siCont and Huh7-siCD133 cells after treatment with 1, 2, and 4 Gy of radiation and pretreatment
with 100 μM SASP. After 10 days, colonies were stained with tryphan blue and counted. b Schematic of experimental procedure in vivo. When
the tumor volume reached 200–250 mm3, mice were randomized to 4 groups (Control, SASP, IR (2Gy), SASP plus IR), and 250 mg/kg sulfasalazine
were injected for 9 days. During the sulfasalazine injection, mice were irradiated with 2Gy dose for 4 days (left panel). The volume of the tumor
was examined every 2 days in the indicated groups. Data are mean ± SD for three animals in each group (right panel). c Immunostaining of
CD133 in Huh7 tumors of indicated groups in xenografted mice
Song et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:38 Page 12 of 15
chemotherapy [32]. CSCs are considered the ‘Achilles
heel’ of anticancer efforts, due to their strong resistance
to chemotherapy and radiotherapy. Recent studies indi-
cate that HCC progression and drug resistance might be
derived from CSCs [33]. Papers have shown that CSC-
related surface markers and pathways can modulate
tumor development and suppression in liver cancer [9,
34–36]. Although the existence of CSCs in solid human
tumors is widely accepted, details of their origin and the
source of their chemoresistance are unclear [37]. In real-
ity, the culture and functional study of CSCs are difficult
in vitro, because CSC enrichment is rapidly lost in artifi-
cial culture systems [38]. In order to overcome this, we
applied an alternative approach to enrich the CSC popu-
lation by manipulating 3D culture conditions. From
these attempts, we discovered that characteristics and
population of CSCs are controlled by changes in the
tumor microenvironment, and that CD133-positive
HCC cells have CSC-like properties to maintain tumor
survival from anti-cancer therapies (Fig. 1). CD133/Pro-
minin-1 has attracted considerable attention as a repre-
sentative liver CSC marker. Indeed, liver cancer patients
with high CD133 expression levels were found to have
shorter overall survival and higher recurrence rates
than patients with low CD133 expression (13). Studies
have shown that CD133-positive liver CSCs can induce
aberrant signaling pathways different from those in
CD133-negative cells, such as the Akt/PKB pathway,
JNK, mTOR, ERK, and β-catenin etc. [9, 39, 40]. How-
ever, the specific mechanism of action by which CD133
CSCs are able to avoid conventional therapies in HCC
remains unknown. Here, we revealed that HCC cells
with high CD133 expression levels have a strong cap-
acity for ROS defense compared to HCC cells with low
levels of CD133 expression (Figs. 2, 3 and 4). Although
the mechanisms regulating the expression of CD133 in
hypoxic conditions are known [41], the detailed mech-
anism by which CD133 expression is upregulated in re-
sponse to oxidative stress has not been elucidated. Here,
our data showed that CD133 expression is increased in
HCC in response to oxidative stress (Fig. 2e, f ).
Recently, the correlation between ROS status and
chemo- and radio-resistance in CSCs has been revealed
in diverse cancers. A subset of CSCs exhibits enhanced
ROS defense compared to non-tumorigenic cells in
breast tumors [19] and lower intracellular concentra-
tions of ROS and ATP can be used as indicators of CSCs
in lung cancer [20]. However, the mechanisms by which
CSCs maintain lower levels of ROS in HCC remain hith-
erto unknown.
In the present study, we have found that CD133-
positive HCC cells control intracellular ROS level via the
upregulating of GSH and sulfasalazine (SASP) not only
alleviates ROS defense capacity but also increases the
therapeutic efficacy of conventional anticancer therapy
in CD133-positive HCC cells but not in CD133-negative
HCC cells in vivo and in vitro.
Actually, this kind of mechanism was proposed by
Ishimoto et al. for another stem-like protein, CD44 [22].
They demonstrated that ablation of CD44 induced loss
of xCT from the cell surface and suppressed tumor
growth in gastric cancer. Here, we examined a potential
cross-talk between CD133 and CD44 on ROS status
(Fig. 3b) and we found that CD133-positive cells per-
form defense against ROS with proposed mechanism
which is indifferent of CD44 expression in HCC.
In this study, we pre-treated sulfasalazine (SASP) be-
fore treating anti-cancer drugs or radiation. We would
like to emphasize the SASP with sensitizer for increasing
the drug efficiency through increasing the ROS accumu-
lation and decreasing the GSH. Additionally, we could
hypothesis that CD133 inhibits ROS resistance through
the maintenance of ROS-induced increasing xCT ex-
pression in CD133-positive HCC cells, and thereby
plays a central role in resistance to liver cancer therapy.
xCT inhibition by treatment with SASP could sensitize
CD133-positive HCC cells to available anticancer
therapies.
SASP not only alleviates ROS defense capacity but also
increases the therapeutic efficacy of conventional anti-
cancer therapy in CD133-positive HCC cells but not in
CD133-negative HCC cells in vivo and in vitro (Figs. 5
and 6). To date, no single agent or combination therapy
has demonstrated any advantage in terms of both overall
survival and quality of life, representing an unmet need.
Combination therapy has not improved overall survival
but has nonetheless been in wide use for many years be-
cause of its possible roles in palliation. Thus, we herein
suggest that combination therapy with SASP and exist-
ing anticancer therapies should be feasible for patients
with HCC without imposing side effects, since SASP is
already approved to treat rheumatoid arthritis without
safety issues. Given that CD133-positive HCC cells play
a central role in resistance to cancer therapy, we believe
that selective inhibition of the CD133-positive HCC
population by pretreatment with SASP should surpass
the limitations of the existing treatment of liver cancer.
Conclusions
In the conclusion, our results provide clear evidence that
CD133 elevates ROS resistance through enhancing of
glutathione (GSH) levels, and thereby plays a central role
in resistance to liver cancer therapy. GHS inhibition by
treatment with SASP sensitizes CD133-positive HCC to
available anticancer therapies. Therefore, our results sug-
gest that a combination of sulfasalazine and conven-
tional chemotherapy might be a promising approach to
overcoming resistance to therapy in liver cancer.
Song et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:38 Page 13 of 15
Additional file
Additional file 1: Figure S1. Liver cancer stem cell (LCSC) spheroids
express a lower level of hepatocyte-related mRNA and higher level of
stem cell-related mRNA compared to hepatocellular carcinoma cell (HCC)
spheroids. Figure S2. LCSC spheroids have strong resistance to anti-
cancer drugs compared to HCC spheroid. Figure S3. Knockdown of
CD133 (Depletion of CD133) does not affect the antioxidant gene in
HCC. Figure S4. Sulfasalazine (SASP) inhibits activity of GSH in CD133-
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